尼妥珠单抗联合顺铂及放疗治疗中晚期宫颈癌的血清肿瘤标志物及病灶癌细胞增殖的评估

Assessment of the serum tumor markers and lesion cancer cell proliferation after Nimotuzumab combined with cisplatin and radiotherapy treatment of middle-advanced cervical cancer

目的:探讨尼妥珠单抗联合顺铂及放疗治疗中晚期宫颈癌后血清肿瘤标志物及病灶癌细胞增殖基因表达量变化。方法:收集在本院接受治疗的中晚期宫颈癌患者78例,按照单盲随机对照法将入组患者分为接受常规放化疗的对照组39例、接受尼妥珠单抗联合顺铂及放疗的观察组39例,均接受为期6周的治疗。治疗前、治疗6周后,采用酶联免疫吸附法(ELISA)检测血清肿瘤标志物含量,采用荧光定量PCR法测定病灶增殖基因mRNA表达量。结果:治疗前,两组血清肿瘤标志物含量,病灶增殖基因mRNA表达量差异无统计学意义(P>0.05)。治疗6周后,观察组血清中肿瘤标志物SCC、CA125、CA19-9含量低于对照组,病灶中促增殖基因B7-H4、HIF-1α、Sp2、PCNA mRNA表达量低于对照组,病灶中抗增殖基因PTEN、FHIT、STC1mRNA表达量高于对照组(P<0.05)。结论:尼妥珠单抗联合顺铂及放疗可有效降低中晚期宫颈癌患者的血清肿瘤标志物含量,同时抑制病灶癌细胞增殖。

Objective：To study the change of serum tumor markers and lesion cancer cell proliferation gene expression after Nimotuzumab combined with cisplatin and radiotherapy treatment of middle-advanced cervical cancer.Methods：78patients with middle-advanced cervical cancer who were treated in our hospital between August 2013 and February 2016 were collected and divided into the control group（n=39）who received routine radiotherapy and chemotherapy and the observation group（n=39）who received Nimotuzumab combined with cisplatin and radiotherapy according to the single-blind randomized control method,and both groups were treated for 6weeks.Before treatment and after 6weeks of treatment,enzyme-linked immunosorbent assay（ELISA）was used to detect serum tumor marker levels,and fluorescence quantitative PCR method was used to detect the lesion proliferation gene mRNA expression.Results：Before treatment,the differences in serum tumor marker levels and lesion proliferation gene mRNA expression were not statistically significant between two groups of group（P〈0.05）.After 6weeks of treatment,serum tumor markers SCC,CA125 and CA19-9levels of observation group were lower than those of control group,lesion pro-proliferation genes B7-H4,HIF-1α,Sp2 and PCNA mRNA expression were lower than those of control group,and lesion anti-proliferation genes PTEN,FHIT and STC1 mRNA expression were higher than those of control group（P〈0.05）.Conclusion：Nimotuzumab combined with cisplatin and radiotherapy can effectively reduce the serum tumor marker levels,and also inhibit the lesion cancer cell proliferation in patients with middle-advanced cervical cancer.